About the Authors
- Rui-Ru Ji, Heshani de Silva, Jian Cao, Aiqing He, Wenjun Huang, Paul S. Kayne, Isaac M. Neuhaus, Karl-Heinz Ott, Becky Penhallow, Mark I. Cockett, Michael G. Neubauer, Nathan O. Siemers, Petra Ross-Macdonald
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey, United States of America
- Yisheng Jin
- Johnson Graduate School of Management, Cornell University, Ithaca, New York, United States of America
- Robert E. Bruccoleri
- Congenomics, Glastonbury, Connecticut, United States of America
The authors are current and previous employees of Bristol-Myers Squibb, who is the manufacturer of dasatinib (one of the compounds included in the study).
Performed the experiments: HdS JC AH WH BP. Analyzed the data: RRJ YJ KHO PRM. Contributed reagents/materials/analysis tools: RRJ REB PSK IMN MIC NOS. Wrote the paper: RRJ PRM. Developed the analytical methods described in the manuscript: RRJ. Designed the experiments: HdS. Revised the manuscript: YJ REB KHO NOS. Conceived transcriptional dose response concept: MGN.